SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis

Lin,Li; Zheng,Xiaoxia; Qiu,Chunping; Dongol,Samina; Lv,Qingtao; Jiang,Jie; Kong,Beihua; Wang,Chenguang

doi:10.3892/or.2014.3521

SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis

Authors:
- Li Lin
- Xiaoxia Zheng
- Chunping Qiu
- Samina Dongol
- Qingtao Lv
- Jie Jiang
- Beihua Kong
- Chenguang Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, P.R. China, Department of Obstetrics and Gynecology, Jinan Maternity and Child Care Hospital, Jinan, P.R. China, Department of Pharmaceutical Chemistry, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, P.R. China, Departments of Cancer Biology, Stem Cell Biology and Regenerative Medicine, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
Published online on: October 1, 2014 https://doi.org/10.3892/or.2014.3521
Pages: 2831-2835

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Silent information regulator 1 (SIRT1) is involved in a number of cellular regulatory mechanisms affecting cellular life span, stress resistance, apoptosis and cellular metabolism. Recent studies have revealed that SIRT1 plays a dual role as a tumor suppressor and a tumor promoter in multiple stages of carcinogenesis. Increased lipogenesis has been found in cancer cells, sterol regulatory element binding protein 1 (SREBP1) are nuclear lipogenic transcription factors, which mainly regulate lipogenic processes by activating genes involved in fatty acid and triglyceride biosynthesis. In the present study, we detected expression of SIRT1 in endometrial cancer (EC) and illustrated the relationship between SIRT1 and SREBP1, which indicated that SIRT1 could stimulate endometrial tumor growth through the lipogenic pathway. Gene expression levels of SIRT1 were assayed using quantitative real-time PCR and protein expression levels were detected by western blotting. RNA interference was conducted in order to explore the subsequent effect on tumor cells and on the expression of SREBP1. Expression levels of SIRT1 in EC were found to be significantly higher than in normal endometrium. Knockdown of SIRT1 could downregulate expression of SREBP1 and suppress cell proliferation. These results demonstrated that SIRT1 may play a role as a tumor promoter in EC and can promote endometrial tumor growth by promoting lipogenesis. Our findings suggest that targeting SIRT1 may provide a theoretical basis for the management of EC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Modesitt SC, Hsu JY, Chowbina SR, Lawrence RT and Hoehn KL: Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int J Gycecol Cancer. 22:732–741. 2012. View Article : Google Scholar
3	Santos CR and Schulze A: Lipid metabolism in cancer. FEBS J. 279:2610–2623. 2012. View Article : Google Scholar : PubMed/NCBI
4	Imai S: The molecular mechanism of aging and longevity and the function of Sir2 proteins. Nihon Ronen Igakkai Zasshi. 38:735–739. 2001.(In Japanese).
5	Liu T, Liu PY and Marshall GM: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 69:1702–1705. 2009. View Article : Google Scholar : PubMed/NCBI
6	Katto J, Engel N, Abbas W, Herbein G and Mahlknecht U: Transcription factor NFκB regulates the expression of the histone deacetylase SIRT1. Clin Epigenetics. 5:112013.
7	Song NY and Surh YJ: Janus-faced role of SIRT1 in tumorigenesis. Ann NY Acad Sci. 1271:10–19. 2012. View Article : Google Scholar : PubMed/NCBI
8	Fang Y and Nicholl MB: Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett. 306:10–14. 2011. View Article : Google Scholar : PubMed/NCBI
9	Shimano H: SREBPs: physiology and pathophysiology of the SREBP family. FEBS J. 276:616–621. 2009. View Article : Google Scholar : PubMed/NCBI
10	Swinnen JV, Brusselmans K and Verhoeven G: Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 9:358–365. 2006. View Article : Google Scholar : PubMed/NCBI
11	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
12	Li JN, Mahmoud MA, Han WF, Ripple M and Pizer ES: Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res. 261:159–165. 2000. View Article : Google Scholar : PubMed/NCBI
13	Swinnen JV: Increased lipogenesis in steroid-responsive cancer cells: mechanisms of regulation, role in cancer cell biology and perspectives on clinical applications. Verh K Acad Geneeskd Belg. 63:321–333. 2001.PubMed/NCBI
14	Yang Yu, Morin PJ, Han WF, et al: Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res. 282:132–137. 2003. View Article : Google Scholar : PubMed/NCBI
15	Yahagi N, Shimano H, Hasegawa K, et al: Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer. 41:1316–1322. 2005. View Article : Google Scholar : PubMed/NCBI
16	Li W, Tai Y, Zhou J, et al: Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 11:2348–2358. 2012. View Article : Google Scholar : PubMed/NCBI
17	Nie LY, Lu QT, Li WH, et al: Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncol Rep. 30:1346–1354. 2013.PubMed/NCBI
18	Eberhard Y, Gronda M, Hurren R, et al: Inhibition of SREBP1 sensitizes cells to death ligands. Oncotarget. 2:186–196. 2011.PubMed/NCBI
19	Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
20	Choi HN, Bae JS, Jamiyandorj U, et al: Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep. 26:503–510. 2011.PubMed/NCBI
21	Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P and Sachchidanand: Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun. 401:13–19. 2010. View Article : Google Scholar : PubMed/NCBI
22	Cha EJ, Noh SJ, Kwon KS, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhao G, Cui J, Zhang JG, et al: SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther. 18:920–928. 2011. View Article : Google Scholar : PubMed/NCBI
24	Nakane K, Fujita Y, Terazawa R, et al: Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. Int J Urol. 19:71–79. 2012. View Article : Google Scholar
25	Firestein R, Blander G, Michan S, et al: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 3:e20202008. View Article : Google Scholar : PubMed/NCBI
26	Lai CC, Lin PM, Lin SF, et al: Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 34:1847–1854. 2013.
27	Medes G, Thomas A and Weinhouse S: Metabolism of neoplastic tissue. IV A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13:27–29. 1953.PubMed/NCBI
28	Knight JR and Milner J: SIRT1, metabolism and cancer. Curr Opin Oncol. 24:68–75. 2012. View Article : Google Scholar : PubMed/NCBI
29	Eberlé D, Hegarty B, Bossard P, Ferré P and Foufelle F: SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 86:839–848. 2004.PubMed/NCBI
30	Bengoechea-Alonso MT, Punga T and Ericsson J: Hyperphos-phorylation regulates the activity of SREBP1 during mitosis. Proc Natl Acad Sci USA. 102:11681–11686. 2005. View Article : Google Scholar : PubMed/NCBI
31	Ponugoti B, Kim DH, Xiao Z, et al: SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem. 285:33959–33970. 2010. View Article : Google Scholar : PubMed/NCBI
32	Walker AK, Yang F, Jiang K, et al: Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 24:1403–1417. 2010. View Article : Google Scholar : PubMed/NCBI
33	Defour A, Dessalle K, Castro Perez A, et al: Sirtuin 1 regulates SREBP-1c expression in a LXR-dependent manner in skeletal muscle. PLoS One. 7:e434902012. View Article : Google Scholar : PubMed/NCBI
34	Deng X, Zhang W, O-Sullivan I, et al: FoxO1 inhibits sterol regulatory element-binding protein-1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J Biol Chem. 287:20132–20143. 2012. View Article : Google Scholar : PubMed/NCBI
35	Zhang W, Patil S, Chauhan B, et al: FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem. 281:10105–10117. 2006. View Article : Google Scholar : PubMed/NCBI
36	Motta MC, Divecha N, Lemieux M, et al: Mammalian SIRT1 represses forkhead transcription factors. Cell. 116:551–563. 2004. View Article : Google Scholar : PubMed/NCBI
37	Yang Y, Hou H, Haller EM, Nicosia SV and Bai W: Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 24:1021–1032. 2005. View Article : Google Scholar : PubMed/NCBI
38	Frampton G, Ueno Y, Quinn M, et al: The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1. Am J Physiol Gastrointest Liver Physiol. 303:G1202–G1211. 2012. View Article : Google Scholar